Tradestie Institutional Equity Comparison Engine · Market Close Nov 17, 2026

GH vs TEM: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

GH Captures Overall Composite Edge (51.3 HOLD vs 43.5 HOLD), While TEM Leads 4–2 on Growth & Valuation Pillars

GH Overall Winner 6-Pillar Tally: GH 2 – 4 TEM Matrix Metrics: GH 6 – 2 TEM

As of Nov 17, 2026, Guardant Health, Inc. (GH) captures the overall head-to-head institutional edge over Tempus AI, Inc. (TEM) on higher Unified Composite conviction (51.3/100 HOLD vs. 43.5/100 HOLD) after splitting the core matrix 6–2 (led by Growth & Scale, Options & Positioning), while TEM wins 4–2 across the 6-pillar growth and valuation breakdown. GH trades at $143.28 (N/M Forward P/E, -39.4% operating margin) versus TEM at $63.43 (N/M Forward P/E, -18.5% operating margin).

  • Growth vs. Quality Trade-Off: GH earns the overall head-to-head edge with a stronger Unified Composite Score (51.3/100 HOLD vs. TEM 43.5/100 HOLD) and 1.31β · 55% Vol risk profile, whereas TEM leads top-line expansion (+23.1% YoY revenue growth, N/M PEG, and 4 of 6 institutional pillars) for higher-beta growth mandates.
  • Technical & Structure Timing Caution: GH trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 35.0); meanwhile TEM is in a Breakdown options structure phase (RSI 40.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About GH vs TEM
GH NASDAQ Head-to-Head Winner
Guardant Health, Inc. Common Stock
Services-Medical Laboratories
$143.28
-0.52% 1D
Market Cap $20.5B
TTM Revenue $1.28B
Forward P/E N/M
Beta / 30D Vol 1.31β · 55% Vol
Unified Composite Score
51.3 / 100 HOLD
Tech 35.0 Fund 51.0 Flow 67.0 Mom 60.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 35
RSI-14: 35.0 · SMA20: $163.98 · SMA50: $167.97
TEM NASDAQ
Tempus AI, Inc. Class A Common Stock
Services-Computer Programming, Data Processing, Etc.
$63.43
-2.05% 1D
Market Cap $13.1B
TTM Revenue $1.51B
Forward P/E N/M
Beta / 30D Vol 2.51β · 93% Vol
Unified Composite Score
43.5 / 100 HOLD
Tech 31.0 Fund 51.0 Flow 67.0 Mom 60.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 40
RSI-14: 40.3 · SMA20: $73.18 · SMA50: $72.83

6-Pillar Scorecard Institutional Category Breakdown (GH 2 – 4 TEM)

Columns: Metric · GH · TEM
1. Valuation Multiples TEM
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue 16.6x 9.2x
2. Growth & Scale GH
Revenue Growth (YoY) +36.1% +23.1%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $1.28B $1.51B
Market Cap $20.5B $13.1B
3. Profitability & Quality TEM
Gross Margin 65.2% 64.5%
Operating Margin -39.4% -18.5%
Net Profit Margin -37.9% -12.5%
Return on Equity (ROE) 0.0% -37.5%
4. Balance Sheet & Cash Flow TEM
Cash Generation (TTM) -$232M -$151M
Cash Flow Margin -18.2% -10.0%
Net Cash / Leverage $665M Net Debt $841M Net Debt (2.86x D/E)
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning GH
Options Structure Phase CONSOLIDATION BREAKDOWN
Current IV / %ile 72.2% (31st %ile) 99.3% (44th %ile)
Put/Call OI Skew 7.63x (Put-Skewed) 0.49x (Call-Skewed)
OBV Trend / Tech Phase DISTRIBUTION · Neutral DISTRIBUTION · Neutral
6. R&D & Supply-Chain Moat TEM
OpEx & R&D Intensity N/A 83.0% of Rev ($1.25B)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Ecosystem & Network-Effect Moat
Supply-Chain Role Diagnostics & Research Operator Health Information Services Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: GH (6) vs TEM (2)
Institutional Metric GH TEM Criterion Row Edge
Market Capitalization
Scale
$20.5B $13.1B Larger Scale GH
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+36.1% +23.1% Higher Growth GH
Operating Margin (TTM)
Profitability
-39.4% -18.5% Higher Margin TEM
Net Profit Margin
Profitability
-37.9% -12.5% Higher Margin TEM
Return on Equity (ROE)
Capital Efficiency
0.0% -37.5% Higher ROE GH
52-Week Range Position
Momentum
59% ($75–$191) 47% ($41–$89) Stronger Trend GH
Beta / 30D Volatility
Risk Regime
1.31β · 55% Vol 2.51β · 93% Vol Lower Realized Risk GH
Unified Institutional Score
Composite Signal
51.3 / 100 (HOLD) 43.5 / 100 (HOLD) Higher Composite GH
Trailing 12M Revenue (USD)
Operating Scale
$1.28B $1.51B FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
65.2% 64.5% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 16.6x EV/Rev N/M PEG · 9.2x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$232M ($665M Net Debt) -$151M ($841M Net Debt (2.86x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon TEM +7.84 pp
GH: -9.25% · TEM: -1.41%
3M Horizon TEM +15.84 pp
GH: -12.28% · TEM: +3.56%
6M Horizon GH +6.61 pp
GH: +45.92% · TEM: +39.31%
1Y Horizon GH +59.2 pp
GH: +51.83% · TEM: -7.37%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period GH Revenue TEM Revenue GH Op. Margin TEM Op. Margin Margin Leader
FY2018 $90M N/A -102.5% N/A GH
FY2019 $210M N/A -38.4% N/A GH
FY2020 $290M N/A -88.9% N/A GH
FY2021 $370M N/A -110.0% N/A GH
FY2022 $450M $320M -121.1% -82.8% TEM
FY2023 $560M $530M -100.1% -36.9% TEM
FY2024 $740M $690M -60.0% -99.7% GH
FY2025 $980M $1.27B -44.5% -19.9% TEM

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
GH CONSOLIDATION
97d in phase · OBV DISTRIBUTION
Current IV 72.2%
IV Percentile 31st %ile
Put/Call OI Skew 7.63x (Put-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BEARISH
OBV Flow DISTRIBUTION
Exact GH Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
TEM BREAKDOWN
36d in phase · OBV DISTRIBUTION
Current IV 99.3%
IV Percentile 44th %ile
Put/Call OI Skew 0.49x (Call-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow DISTRIBUTION
Exact TEM Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
LIVE OPTIONS CHAIN · T+5 TRADING DAY HORIZON Spot $144.52 · IV 57.1%

GH vs. TEM: Simulated 5-Day Option Payoffs & Capital Efficiency

Compare 100 shares of GH ($14,452) vs. TEM ($6,476) against risk-defined 5-day vertical and put-wall option structures.

GH Spot $144.52 · IV 57.1%
GH Options Simulator →
PUT-WALL MONTHLY INCOME Liq B

Jan 15 '27 $135 / $120 Bull Put Spread

Sell 1x $135P · Buy 1x $120P · 59d

Net Entry $379 Credit
Max Credit / Yield +$379 (+33.8% RoM)
Max Risk / Buffer -9.2% Cushion ($1,121 Mgn)
5d Edge & Liquidity 67% PoP · Liq B
Simulate 5-Day Payoff →
5-DAY DOWNSIDE SPREAD Liq B

Dec 18 $150 / $140 Bear Put Spread

Buy 1x $150P · Sell 1x $140P · 31d

Net Entry $512 Debit
T+5d @ -5% Drop +$130 (+25%)
Max Risk / Buffer $512 Capped
5d Edge & Liquidity 0.8x R:R · Liq B
Simulate 5-Day Payoff →
TEM Spot $64.76 · IV 84.1%
TEM Options Simulator →
5-DAY BULLISH SWING Liq A

Dec 18 $65 / $75 Bull Call Spread

Buy 1x $65C · Sell 1x $75C · 32d

Net Entry $365 Debit
T+5d @ +5% Move +$69 (+19%)
Max Risk / Buffer $365 Capped
5d Edge & Liquidity 0.7x R:R · Liq A
Simulate 5-Day Payoff →
PUT-WALL MONTHLY INCOME Liq A

Dec 18 $60 / $55 Bull Put Spread

Sell 1x $60P · Buy 1x $55P · 32d

Net Entry $160 Credit
Max Credit / Yield +$160 (+47.1% RoM)
Max Risk / Buffer -9.8% Cushion ($340 Mgn)
5d Edge & Liquidity 68% PoP · Liq A
Simulate 5-Day Payoff →

Simulated T+5 trading day payoffs use live option midpoints, bid-ask spread adjustments, and implied volatility skew for educational scenario modeling only — not personalized investment advice. Options involve substantial risk.

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
GH Moat Profile Cyclical / Execution-Driven Positioning
Diagnostics & Research Operator
Competes within the Diagnostics & Research value chain with $20.5B market capitalization and -39.4% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
TEM Moat Profile Ecosystem & Network-Effect Moat
Health Information Services Operator
Competes within the Health Information Services value chain with $13.1B market capitalization and -18.5% operating margin.
OpEx & R&D Reinvestment 83.0% of Rev ($1.25B)
90D Engineering Disclosures 0 Published · AI Drug Discovery

Investor FAQ GH vs TEM Key Questions & Quantitative Answers

As of Nov 17, 2026, Guardant Health, Inc. (GH) captures the overall head-to-head institutional edge over Tempus AI, Inc. (TEM) on higher Unified Composite conviction (51.3/100 HOLD vs. 43.5/100 HOLD) after splitting the core matrix 6–2 (led by Growth & Scale, Options & Positioning), while TEM wins 4–2 across the 6-pillar growth and valuation breakdown. GH trades at $143.28 (N/M Forward P/E, -39.4% operating margin) versus TEM at $63.43 (N/M Forward P/E, -18.5% operating margin). Growth vs. Quality Trade-Off: GH earns the overall head-to-head edge with a stronger Unified Composite Score (51.3/100 HOLD vs. TEM 43.5/100 HOLD) and 1.31β · 55% Vol risk profile, whereas TEM leads top-line expansion (+23.1% YoY revenue growth, N/M PEG, and 4 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: GH trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 35.0); meanwhile TEM is in a Breakdown options structure phase (RSI 40.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

GH leads the Growth & Scale pillar: GH posts +36.1% YoY revenue growth and +0.0% YoY earnings growth on $1.28B TTM revenue (65.2% gross margin, -39.4% operating margin), compared with TEM at +23.1% YoY revenue growth and +0.0% YoY earnings growth on $1.51B TTM revenue (64.5% gross margin, -18.5% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), GH cumulative revenue shifted +988.9% while TEM shifted +296.9%. In operating R&D and SG&A reinvestment, GH deploys N/A (0 90-day corporate R&D disclosures) versus 83.0% of Rev ($1.25B) (0 disclosures) for TEM.

TEM screens cheaper on headline valuation multiples. GH trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 16.6x EV/Revenue (-18.2% FCF margin), whereas TEM trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 9.2x EV/Revenue (-10.0% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against GH (0.0% ROE) versus TEM (-37.5% ROE) capital efficiency.

In options market volatility and institutional positioning, GH carries 72.2% implied volatility (31st %ile, Balanced (25th–60th %ile)), a 7.63x (Put-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (1.31β · 55% Vol realized risk). By comparison, TEM carries 99.3% implied volatility (44th %ile, Balanced (25th–60th %ile)), a 0.49x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (2.51β · 93% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 17, 2026. For educational research only; not investment advice.